F2 and pertussis: Considering the high immunogenicity of PTgen, we postulated that lower-dose and therefore cost-saving formulations of the licensed recombinant pertussis vaccines may be suitable candidates for maternal pertussis immunization in low-to-middle income countries if shown to induce sufficiently high PT antibody levels that may be assumed to protect newborns against severe pertussis in the first months of life.